Lasanta, MAL, Saborit, MC, Panos, HB, Lizarzaburu, MS, Ruiz-Esquide, V, Vilaseca, DR, Nack, A, Perez-Garcia, C, Bernarde, J, Guillen, AG, Aguilar, JR, Cuervo, A, Valls, M, Gomez, CG, Minguez, S, Novell, RM, Alarcon, PE, Martinez-Morillo, M, Grau, CP, Busquets-Perez, N, Park, HS, Gomez-Puerta, JA, Perez, SH, Palau, NM, Sanmarti, R, Mateo-Soria, L, Diaz-Torne, C, Coromina, H, Alarcon, GS. COMPARISON OF BARICITINIB AND TOFACITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: INSIGHTS FROM A REAL-WORLD COHORT USING PROPENSITY SCORE ADJUSTMENTS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B2477. PMID:. IF:20.600(Q1/1D).

Salman-Monte, TC, Carrion-Barberá, I, Triginer, L, Riveros-Frutos, A, Font, J, Garcia-Villanueva, MJ, Garrote-Corral, S, Galindo, M, Polo, CD, González, IA, Bernabéu, P, Casasempere, PV, Morales, CM, Alvarez, ED, Cortés-Hernández, J, Moreno, SS, Giráldez, CR, Gil, JJF, Hernández, A, Magallares, BP, Garcia, MMP, Cid, CMF, Hernández, S, Ros, I, García-Aparicio, A, Sala-Icardo, L, Gómez-Puerta, JA, Frade-Sosa, B, Garcia-Cirera, S, Bufort, MG, Martínez-Barrio, J, de Salazar, JRG, del Amo, ND, Fito-Manteca, C, Torrente-Segarra, V, Heredia, S, Brandy-Garcia, A, Lucea, ER, Zarrabeitia, LR, Urruticoechea-Arana, A, Pego-Reigosa, JM, Rúa-Figueroa, IJ. AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1338. PMID:. IF:20.600(Q1/1D).

Bjorkekjaer, HJ, Bruni, C, Broch, K, Brunborg, C, Carreira, PE, Airò, P, Simeón-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, CP, Gabrielli, A, Del Galdo, F, Vonk, MC, Fretheim, H, Bitter, H, Midtvedt,O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellví, I, Siegert, E, Hachulla, E, Molberg,O, Distler, O, Hoffmann-Vold, AM, EUSTAR Collaborators. A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf053. PMID:39878955. IF:4.400(Q1/1D).

Ochsenreither, S, Anguera, G, Dieter, S, Trikalinos, N, Fu, SQ, Fernández, BC, Ferrandiz, AC, Kim, SY, Rodriguez, LM, Berg, KCG, Hassan, HIB, Rosholm, A, Fredriksen, AB. Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(16_SUPPL)DOI:10.1200/JCO.2025.43.16_suppl.2639. PMID:. IF:41.900(Q1/1D).

Herbst, RS, John, T, Grohé, C, Goldman, JW, Kato, T, Laktionov, K, Bonanno, L, Tiseo, M, Majem, M, Dómine, M, Ahn, MJ, Kowalski, DM, Pérol, M, Sriuranpong, V, Özgüroglu, M, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Robichaux, J, Hartmaier, R, Tsuboi, M, Wu, YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. NATURE MEDICINE. 2025; 31(6)DOI:10.1038/s41591-025-03577-y. PMID:40097663. IF:50.000(Q1/1D).

Tibau, A, Cliff, ERS, Romano, A, Borrell, M, Molto, C, Kesselheim, AS. Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study. Eclinicalmedicine. 2025; 84DOI:10.1016/j.eclinm.2025.103088. PMID:40687736. IF:10.000(Q1/1D).

Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).

Barroeta, I, Videla, L, Carmona-Iragui, M, Fortea, J, Rafii, MS. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70258. PMID:40528298. IF:11.100(Q1/1D).